CTOs on the Move

Institute for Clinical Evaluative Sciences

www.ices.on.ca

 
Institute for Clinical Evaluative Sciences is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ices.on.ca
  • 2075 Bayview Ave
    Toronto, ON CAN M4N 3M5
  • Phone: 416.480.6100

Executives

Name Title Contact Details

Similar Companies

LigoCyte Pharmaceuticals

LigoCyte Pharmaceuticals, Inc is a Bozeman, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

1910 Genetics

We are a biotechnology company integrating AI, computation and biological automation to accelerate the design of small molecule and protein therapeutics. Our mission is to decrease the timeline and cost of drug development, while improving the success rate of bring innovative medicines to patients in need.

Aimmune

Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company`s Characterized Oral Desensitization ImmunoTherapy (CODITâ„¢) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies. Aimmune is located in Brisbane, California - the heart of San Francisco`s biotechnology hub - with additional offices in the Kings Cross area of London and in Durham, North Carolina.

KBI BioPharma

KBI BioPharma is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrack

Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer`s.